Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Heme oxygenase is not involved in the anti-proliferative effects of statins on pancreatic cancer cells

K. Vanova, S. Boukalova, H. Gbelcova, L. Muchova, J. Neuzil, R. Gurlich, T. Ruml, L. Vitek,

. 2016 ; 16 (-) : 309. [pub] 20160512

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc18017255

Grantová podpora
NT13112 MZ0 CEP - Centrální evidence projektů
NT14078 MZ0 CEP - Centrální evidence projektů

BACKGROUND: Pancreatic cancer is recognized as one of the most fatal tumors due to its aggressiveness and resistance to therapy. Statins were previously shown to inhibit the proliferation of cancer cells via various signaling pathways. In healthy tissues, statins activate the heme oxygenase pathway, nevertheless the role of heme oxygenase in pancreatic cancer is still controversial. The aim of this study was to evaluate, whether anti-proliferative effects of statins in pancreatic cancer cells are mediated via the heme oxygenase pathway. METHODS: In vitro effects of various statins and hemin, a heme oxygenase inducer, on cell proliferation were evaluated in PA-TU-8902, MiaPaCa-2 and BxPC-3 human pancreatic cancer cell lines. The effect of statins on heme oxygenase activity was assessed and heme oxygenase-silenced cells were used for pancreatic cancer cell proliferation studies. Cell death rate and reactive oxygen species production were measured in PA-TU-8902 cells, followed by evaluation of the effect of cerivastatin on GFP-K-Ras trafficking and expression of markers of invasiveness, osteopontin (SPP1) and SOX2. RESULTS: While simvastatin and cerivastatin displayed major anti-proliferative properties in all cell lines tested, pravastatin did not affect the cell growth at all. Strong anti-proliferative effect was observed also for hemin. Co-treatment of cerivastatin and hemin increased anti-proliferative potential of these agents, via increased production of reactive oxygen species and cell death compared to individual treatment. Heme oxygenase silencing did not prevent pancreatic cancer cells from the tumor-suppressive effect of cerivastatin or hemin. Cerivastatin, but not pravastatin, protected Ras protein from trafficking to the cell membrane and significantly reduced expressions of SPP1 (p < 0.05) and SOX2 (p < 0.01). CONCLUSIONS: Anti-proliferative effects of statins and hemin on human pancreatic cancer cell lines do not seem to be related to the heme oxygenase pathway. While hemin triggers reactive oxygen species-induced cell death, cerivastatin targets Ras protein trafficking and affects markers of invasiveness.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18017255
003      
CZ-PrNML
005      
20191023083825.0
007      
ta
008      
180515s2016 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12885-016-2343-9 $2 doi
035    __
$a (PubMed)27175805
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Váňová, Kateřina $u Institute of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University in Prague, Katerinska 32, Prague 2, 120 00, Czech Republic. $7 _BN007785
245    10
$a Heme oxygenase is not involved in the anti-proliferative effects of statins on pancreatic cancer cells / $c K. Vanova, S. Boukalova, H. Gbelcova, L. Muchova, J. Neuzil, R. Gurlich, T. Ruml, L. Vitek,
520    9_
$a BACKGROUND: Pancreatic cancer is recognized as one of the most fatal tumors due to its aggressiveness and resistance to therapy. Statins were previously shown to inhibit the proliferation of cancer cells via various signaling pathways. In healthy tissues, statins activate the heme oxygenase pathway, nevertheless the role of heme oxygenase in pancreatic cancer is still controversial. The aim of this study was to evaluate, whether anti-proliferative effects of statins in pancreatic cancer cells are mediated via the heme oxygenase pathway. METHODS: In vitro effects of various statins and hemin, a heme oxygenase inducer, on cell proliferation were evaluated in PA-TU-8902, MiaPaCa-2 and BxPC-3 human pancreatic cancer cell lines. The effect of statins on heme oxygenase activity was assessed and heme oxygenase-silenced cells were used for pancreatic cancer cell proliferation studies. Cell death rate and reactive oxygen species production were measured in PA-TU-8902 cells, followed by evaluation of the effect of cerivastatin on GFP-K-Ras trafficking and expression of markers of invasiveness, osteopontin (SPP1) and SOX2. RESULTS: While simvastatin and cerivastatin displayed major anti-proliferative properties in all cell lines tested, pravastatin did not affect the cell growth at all. Strong anti-proliferative effect was observed also for hemin. Co-treatment of cerivastatin and hemin increased anti-proliferative potential of these agents, via increased production of reactive oxygen species and cell death compared to individual treatment. Heme oxygenase silencing did not prevent pancreatic cancer cells from the tumor-suppressive effect of cerivastatin or hemin. Cerivastatin, but not pravastatin, protected Ras protein from trafficking to the cell membrane and significantly reduced expressions of SPP1 (p < 0.05) and SOX2 (p < 0.01). CONCLUSIONS: Anti-proliferative effects of statins and hemin on human pancreatic cancer cell lines do not seem to be related to the heme oxygenase pathway. While hemin triggers reactive oxygen species-induced cell death, cerivastatin targets Ras protein trafficking and affects markers of invasiveness.
650    _2
$a apoptóza $x účinky léků $7 D017209
650    _2
$a western blotting $7 D015153
650    _2
$a pohyb buněk $x účinky léků $7 D002465
650    _2
$a proliferace buněk $x účinky léků $7 D049109
650    _2
$a hemoxygenasa-1 $x genetika $x metabolismus $7 D051547
650    _2
$a lidé $7 D006801
650    _2
$a statiny $x farmakologie $7 D019161
650    _2
$a pankreas $x metabolismus $7 D010179
650    _2
$a nádory slinivky břišní $x farmakoterapie $x metabolismus $x patologie $7 D010190
650    _2
$a messenger RNA $x genetika $7 D012333
650    _2
$a reaktivní formy kyslíku $x metabolismus $7 D017382
650    _2
$a kvantitativní polymerázová řetězová reakce $7 D060888
650    _2
$a polymerázová řetězová reakce s reverzní transkripcí $7 D020133
650    _2
$a signální transdukce $7 D015398
650    _2
$a nádorové buňky kultivované $7 D014407
650    _2
$a ras proteiny $x genetika $x metabolismus $7 D018631
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Boukalová, Štěpána $u Institute of Biotechnology, Czech Academy of Sciences, Videnska 1083, Prague 4, 142 20, Czech Republic. $7 xx0129413
700    1_
$a Gbelcová, Helena $u Department of Biochemistry and Microbiology, University of Chemistry and Technology, Technicka 1905/5, Prague 6, 160 00, Czech Republic. $7 xx0257254
700    1_
$a Muchová, Lucie $u Institute of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University in Prague, Katerinska 32, Prague 2, 120 00, Czech Republic. $7 xx0061466
700    1_
$a Neužil, Jiří, $u Institute of Biotechnology, Czech Academy of Sciences, Videnska 1083, Prague 4, 142 20, Czech Republic. School of Medical Science, Griffith University, Parklands Avenue, 4222, Southport, QLD, Australia. $d 1958- $7 xx0115772
700    1_
$a Gurlich, R $u Department of Surgery, University Hospital Kralovske Vinohrady and Charles University in Prague, Srobarova 50, Prague 10, 100 34, Czech Republic.
700    1_
$a Ruml, Tomáš, $u Department of Biochemistry and Microbiology, University of Chemistry and Technology, Technicka 1905/5, Prague 6, 160 00, Czech Republic. $d 1954- $7 nlk20030128618
700    1_
$a Vítek, Libor, $u Institute of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University in Prague, Katerinska 32, Prague 2, 120 00, Czech Republic. vitek@cesnet.cz. 4th Department of Internal Medicine, 1st Faculty of Medicine, Charles University in Prague, Katerinska 32, Prague 2, 120 00, Czech Republic. vitek@cesnet.cz. $d 1969- $7 xx0035071
773    0_
$w MED00008171 $t BMC cancer $x 1471-2407 $g Roč. 16, č. - (2016), s. 309
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27175805 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20191023084259 $b ABA008
999    __
$a ok $b bmc $g 1300879 $s 1014095
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 16 $c - $d 309 $e 20160512 $i 1471-2407 $m BMC cancer $n BMC Cancer $x MED00008171
GRA    __
$a NT13112 $p MZ0
GRA    __
$a NT14078 $p MZ0
LZP    __
$a Pubmed-20180515

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...